Cara Therapeutics

Share on: 

Developing proprietary compounds to treat pain, inflammation and pruritus (itching) without inducing many of the side effects associated with current therapies.  These products selectively target the body’s peripheral kappa opioid receptors.  Cara is also developing cannabinoid receptor agonsist that selectively modulate peripheral cannabinoid receptors without targeting CNS cannabinoid receptors.

Career Page(s): 
Stamford CT
United States